Orum Therapeutics (A475830) Stock Overview
A biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A475830 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Orum Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩25,400.00 |
| 52 Week High | ₩146,600.00 |
| 52 Week Low | ₩24,450.00 |
| Beta | 0 |
| 1 Month Change | -59.03% |
| 3 Month Change | -55.98% |
| 1 Year Change | -25.29% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 16.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| A475830 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -49.7% | -0.4% | 4.9% |
| 1Y | -25.3% | -18.5% | 90.6% |
Return vs Industry: A475830 underperformed the KR Biotechs industry which returned -18.5% over the past year.
Return vs Market: A475830 underperformed the KR Market which returned 90.6% over the past year.
Price Volatility
| A475830 volatility | |
|---|---|
| A475830 Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.2% |
Stable Share Price: A475830's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A475830's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 24 | SJ Lee | www.orumrx.com |
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It is also involved in the development of multiple programs for the treatment of solid tumors and immunology and inflammation; and E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs.
Orum Therapeutics, Inc. Fundamentals Summary
| A475830 fundamental statistics | |
|---|---|
| Market cap | ₩551.68b |
| Earnings (TTM) | ₩18.51b |
| Revenue (TTM) | ₩40.55m |
Is A475830 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A475830 income statement (TTM) | |
|---|---|
| Revenue | ₩40.55m |
| Cost of Revenue | ₩320.00k |
| Gross Profit | ₩40.23m |
| Other Expenses | -₩18.47b |
| Earnings | ₩18.51b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 852.28 |
| Gross Margin | 99.21% |
| Net Profit Margin | 45,646.42% |
| Debt/Equity Ratio | 37.3% |
How did A475830 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/22 21:00 |
| End of Day Share Price | 2026/09/22 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orum Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.